Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Culture Cells | Devices | DNA | DNA Templates | DNA Testing | Elisa Kits | Enzymes | Exosomes | Gels | Isotypes | Medium & Serums | NATtrol | Panel | Particles | PCR | Pcr Kits | Peptides | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot
Anti-Mitochondrial Tumor Suppressor
Mitochondrial p53 prompts Bak and causes disruption of a Bak-Mcl1 advanced.
- The tumour suppressor exercise of the p53 protein has been defined by its means to induce apoptosis in response to quite a lot of mobile stresses.
- Thus, understanding the mechanism by which p53 features within the execution of cell demise pathways is of appreciable significance in most cancers biology.
- Latest research have indicated that p53 has a direct signalling position at mitochondria within the induction of apoptosis, though the mechanisms concerned usually are not utterly understood.
DNA Polymerase for PAGE Enzyme
- Right here we present that, after cell stress, p53 interacts with the pro-apoptotic mitochondrial membrane protein Bak. Interplay of p53 with Bak causes oligomerization of Bak and launch of cytochrome c from mitochondria.
Guanine Nucleotide Exchange Factor For Rab-3A (RAB3IL1) Antibody
- Notably, we present that formation of the p53-Bak advanced coincides with lack of an interplay between Bak and the anti-apoptotic Bcl2-family member Mcl1. These outcomes are in step with a mannequin through which p53 and Mcl1 have opposing results on mitochondrial apoptosis by interacting with, and modulating the exercise of, the demise effector Bak.
VHL Antibody |
|||
32075-100ul | SAB | 100ul | EUR 302.4 |
VHL Antibody |
|||
1-CSB-PA991849 | Cusabio |
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:10000, IHC:1:50-1:200 |
VHL Antibody |
|||
CSB-PA025852KA01HU- | Cusabio | each | EUR 402 |
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Antibody |
|||
CSB-PA025852KA01HU-100ul | Cusabio | 100ul | EUR 466.8 |
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Antibody |
|||
E18-6292-1 | EnoGene | 50μg/50μl | EUR 145 |
Description: Available in various conjugation types. |
VHL Antibody |
|||
E18-6292-2 | EnoGene | 100μg/100μl | EUR 225 |
Description: Available in various conjugation types. |
VHL Antibody |
|||
E19-6104 | EnoGene | 100μg/100μl | EUR 225 |
Description: Available in various conjugation types. |
VHL Antibody |
|||
F49681-0.05ML | NSJ Bioreagents | 0.05 ml | EUR 140.25 |
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. |
VHL Antibody |
|||
F49681-0.2ML | NSJ Bioreagents | 0.2 ml | EUR 322.15 |
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. |
VHL Antibody |
|||
F49682-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. |
VHL Antibody |
|||
F49682-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 330.65 |
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. |
VHL Antibody |
|||
E312859 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
VHL Antibody |
|||
E90377 | EnoGene | 100ul | EUR 255 |
Description: Available in various conjugation types. |
VHL Antibody |
|||
DF6104 | Affbiotech | 200ul | EUR 420 |
VHL Antibody |
|||
DF6104-100ul | Affinity Biosciences | 100ul | EUR 280 |
VHL Antibody |
|||
DF6104-200ul | Affinity Biosciences | 200ul | EUR 350 |
VHL Antibody |
|||
AF6292 | Affbiotech | 200ul | EUR 420 |
VHL Antibody |
|||
AF6292-100ul | Affinity Biosciences | 100ul | EUR 280 |
VHL Antibody |
|||
AF6292-200ul | Affinity Biosciences | 200ul | EUR 350 |
VHL antibody |
|||
70R-34605 | Fitzgerald | 100 ug | EUR 294 |
Description: Purified Rabbit polyclonal VHL antibody |
VHL antibody |
|||
70R-9757 | Fitzgerald | 50 ug | EUR 467 |
Description: Affinity purified rabbit polyclonal VHL antibody |
VHL Antibody |
|||
ABD6104 | Lifescience Market | 100 ug | EUR 525.6 |
VHL antibody |
|||
CAF50371-100ug | Biomatik Corporation | 100ug | EUR 338 |
VHL Antibody |
|||
1-CSB-PA060067 | Cusabio |
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000 |
VHL Antibody |
|||
1-CSB-PA071125 | Cusabio |
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
VHL Antibody |
|||
1-CSB-PA876839 | Cusabio |
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000 |
VHL Antibody |
|||
ABF6292 | Lifescience Market | 100 ug | EUR 525.6 |
VHL Antibody |
|||
GWB-MV584H | GenWay Biotech | 50ug | Ask for price |
VHL Antibody |
|||
R35773-100UG | NSJ Bioreagents | 100 ug | EUR 339.15 |
Description: Additional name(s) for this target protein: Von Hippel-Lindau tumor suppressor, VHL1 |
anti- VHL antibody |
|||
FNab10175 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against VHL |
anti- VHL antibody |
|||
FNab09402 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against VHL |
Human VHL Antibody |
|||
32825-05111 | AssayPro | 150 ug | EUR 215 |
VHL (pS68) Antibody |
|||
abx219320-100ug | Abbexa | 100 ug | EUR 526.8 |
OAPA00188-5UG - VHL Antibody |
|||
OAPA00188-5UG | Aviva Systems Biology | 5ug | EUR 69 |
OAAF08344-50UL - VHL Antibody |
|||
OAAF08344-50UL | Aviva Systems Biology | 50ul | EUR 219 |
Rabbit Polyclonal VHL Antibody |
|||
TA327866 | Origene Technologies GmbH | 100 µl | Ask for price |
OAAJ06578-100UL - VHL Antibody |
|||
OAAJ06578-100UL | Aviva Systems Biology | 100uL | EUR 319 |
OAAF01679-100UG - VHL Antibody |
|||
OAAF01679-100UG | Aviva Systems Biology | 100ug | EUR 329 |
OAAF08344-100UL - VHL Antibody |
|||
OAAF08344-100UL | Aviva Systems Biology | 100ul | EUR 329 |
VHL Polyclonal Antibody |
|||
E046866 | EnoGene | 100μg/100μl | EUR 255 |
Description: Available in various conjugation types. |
VHL Polyclonal Antibody |
|||
E11-2035988 | EnoGene | 100ug/100ul | EUR 225 |
Description: Available in various conjugation types. |
VHL Polyclonal Antibody |
|||
E911240 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
VHL Polyclonal Antibody |
|||
E916287 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
VHL Polyclonal Antibody |
|||
E20-74876 | EnoGene | 100ug | EUR 225 |
Description: Available in various conjugation types. |
VHL Polyclonal Antibody |
|||
46866 | SAB | 100ul | EUR 319 |
VHL Polyclonal Antibody |
|||
46866-100ul | SAB | 100ul | EUR 302.4 |
VHL Polyclonal Antibody |
|||
46866-50ul | SAB | 50ul | EUR 224.4 |
VHL Conjugated Antibody |
|||
C32075 | SAB | 100ul | EUR 476.4 |
VHL Polyclonal Antibody |
|||
ABP56500-003ml | Abbkine | 0.03ml | EUR 189.6 |
Description: A polyclonal antibody for detection of VHL from Human, Mouse, Rat. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human VHL around the non-phosphorylation site of S68 |
VHL Polyclonal Antibody |
|||
ABP56500-01ml | Abbkine | 0.1ml | EUR 346.8 |
Description: A polyclonal antibody for detection of VHL from Human, Mouse, Rat. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human VHL around the non-phosphorylation site of S68 |
VHL Polyclonal Antibody |
|||
ABP56500-02ml | Abbkine | 0.2ml | EUR 496.8 |
Description: A polyclonal antibody for detection of VHL from Human, Mouse, Rat. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human VHL around the non-phosphorylation site of S68 |
VHL Polyclonal Antibody |
|||
ABP60891-003ml | Abbkine | 0.03ml | EUR 189.6 |
Description: A polyclonal antibody for detection of VHL from Human. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human VHL protein at amino acid sequence of 1-50 |
VHL Polyclonal Antibody |
|||
ABP60891-01ml | Abbkine | 0.1ml | EUR 346.8 |
Description: A polyclonal antibody for detection of VHL from Human. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human VHL protein at amino acid sequence of 1-50 |
VHL Polyclonal Antibody |
|||
ABP60891-02ml | Abbkine | 0.2ml | EUR 496.8 |
Description: A polyclonal antibody for detection of VHL from Human. This VHL antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human VHL protein at amino acid sequence of 1-50 |
VHL Polyclonal Antibody |
|||
E44H06396 | EnoGene | 100ul | EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
VHL Polyclonal Antibody |
|||
E44H07430 | EnoGene | 100ul | EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
VHL Polyclonal Antibody |
|||
E-AB-93053-120uL | Elabscience Biotech | 120uL | EUR 320 |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-93053-200uL | Elabscience Biotech | 200uL | EUR 530 |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-93053-60uL | Elabscience Biotech | 60uL | EUR 200 |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-93053-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-65684-120uL | Elabscience Biotech | 120uL | EUR 320 |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-65684-200uL | Elabscience Biotech | 200uL | EUR 530 |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-65684-60uL | Elabscience Biotech | 60uL | EUR 200 |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-65684-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-66748-120uL | Elabscience Biotech | 120uL | EUR 320 |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-66748-200uL | Elabscience Biotech | 200uL | EUR 530 |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-66748-60uL | Elabscience Biotech | 60uL | EUR 200 |
Description: Unconjugated |
VHL Polyclonal Antibody |
|||
E-AB-66748-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
VHL (Ab-68) Antibody |
|||
E11-8450B | EnoGene | 100μg | EUR 225 |
Description: Available in various conjugation types. |
VHL (Ab-68) Antibody |
|||
8B8450 | AAT Bioquest | 50ug | EUR 368 |
Description: VHL (Ab-68) Antibody |
Polyclonal VHL Antibody (C-term) |
|||
APR10723G | Leading Biology | 0.1ml | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VHL (C-term). This antibody is tested and proven to work in the following applications: |
Human VHL Antibody (Biotin Conjugate) |
|||
32825-05121 | AssayPro | 150 ug | EUR 315 |
VHL (Phospho- Ser68) Antibody |
|||
ABF8334 | Lifescience Market | 100 ug | EUR 525.6 |
VHL (Phospho-Ser68) Antibody |
|||
12654 | SAB | 100ul | EUR 319 |
VHL (Phospho-Ser68) Antibody |
|||
12654-100ul | SAB | 100ul | EUR 302.4 |
VHL (Phospho-Ser68) Antibody |
|||
12654-50ul | SAB | 50ul | EUR 224.4 |
VHL Rabbit Polyclonal Antibody |
|||
ES7499-100ul | ELK Biotech | 100ul | EUR 124 |
Description: A Rabbit Polyclonal antibody against VHL from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA |
VHL Rabbit Polyclonal Antibody |
|||
ES7499-50ul | ELK Biotech | 50ul | EUR 74 |
Description: A Rabbit Polyclonal antibody against VHL from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA |
VHL Rabbit Polyclonal Antibody |
|||
ES8746-100ul | ELK Biotech | 100ul | EUR 124 |
Description: A Rabbit Polyclonal antibody against VHL from Human. This antibody is tested and validated for IHC, WB, ELISA |
VHL Rabbit Polyclonal Antibody |
|||
ES8746-50ul | ELK Biotech | 50ul | EUR 74 |
Description: A Rabbit Polyclonal antibody against VHL from Human. This antibody is tested and validated for IHC, WB, ELISA |
SirT3 suppresses hypoxia inducible issue 1α and tumor development by inhibiting mitochondrial ROS manufacturing.
- The position of oncoproteins and tumor suppressor proteins in selling the malignant transformation of mammalian cells by affecting properties reminiscent of proliferative signalling, cell cycle regulation and altered adhesion is effectively established.
Taq DNA Polymerase (Recombinant)
- Chemical compounds, viruses and radiation are additionally typically accepted as brokers that generally induce mutations within the genes encoding these most cancers-causing proteins, thereby giving rise to most cancers. Nevertheless, more moderen proof signifies the significance of two advertditional key components imposed on proliferating cells which can be concerned in transformation to malignancy and these are hypoxia and/or aggravating circumstances of nutrient deprivation (e.g. lack of glucose).
- These two further triggers can provoke and promote the method of malignant transformation when a low share of cells overcome and escape mobile senescence. It’s turning into obvious that hypoxia causes the progressive elevation in mitochondrial ROS production (continual ROS) which over time results in stabilization of cells through elevated HIF-2alpha expression, enabling cells to outlive with sustained ranges of elevated ROS.
Recombination Signal Binding Protein For Immunoglobulin Kappa J Region (RBPJ) Antibody
- In cells below hypoxia and/or low glucose, DNA mismatch restore processes are repressed by HIF-2alpha and so they frequently accumulate mitochondrial ROS-induced oxidative DNA injury and rising numbers of mutations driving the malignant transformation course of.
- Latest proof additionally signifies that the ensuing mutated most cancers-causing proteins suggestions to amplify the method by immediately affecting mitochondrial operate in combinatorial ways in which intersect to play a serious position in selling a vicious spiral of malignant cell transformation.
- Consequently, many malignant course ofes contain intervals of elevated mitochondrial ROS manufacturing when a number of cells survive the extra frequent technique of oxidative injury induced cell senescence and demise. The few cells escaping elimination emerge with oncogenic mutations and survive to change into immortalized tumors.
- This evaluation focuses on evidence highlighting the position of mitochondria as drivers of elevated ROS manufacturing throughout malignant transformation and therefore, their potential as targets for most cancers remedy. The evaluation is organized into 5 fundamental sections regarding totally different features of “mitochondrial malignancy”.
- The primary considerations the features of mitochondrial ROS and its significance as a pacesetter for cell development versus senescence and demise. The second considers the obtainable proof that mobile stress within the type of hypoxic and/or hypoglycaemic conditions signify two of the main triggering occasions for most cancers and the way oncoproteins reinforce this course of by altering gene expression to deliver a couple of frequent set of modifications in mitochondrial operate and exercise in most cancers cells.
- The third part presents proof that oncoproteins and tumor suppressor proteins bodily localize to the mitochondria in most cancers cells the place they immediately regulate malignant mitochondrial packages, together with apoptosis.
- The fourth part covers frequent mutational modifications within the mitochondrial genome as they relate to malignancy and the connection to the opposite three areas. The final part considerations the relevance of those findings, their significance and significance for novel focused approaches to anti–most cancers remedy and selective triggering in most cancers cells of the mitochondrial apoptotic pathway.
19 mm Diameter Solid Titanium Tip |
|||
0-120-0013 | Biologics | 19 mm | EUR 570 |
25 mm Diameter Tapped Titanium Tip |
|||
0-120-0014 | Biologics | 25 mm | EUR 682 |
25 mm Diameter Solid Titanium Tip |
|||
0-120-0015 | Biologics | 25 mm | EUR 614 |
Flat Replaceable Tips 13 mm Diameter Flat Titanium Tip |
|||
0-120-0016 | Biologics | 13 mm | EUR 86 |
Description: use with corresponding Tapped Tips and Tapped Extender Tips |
Flat Replaceable Tips 19 mm Diameter Flat Titanium Tip |
|||
0-120-0017 | Biologics | 19 mm | EUR 92 |
Description: use with corresponding Tapped Tips and Tapped Extender Tips |
Flat Replaceable Tips 25 mm Diameter Flat Titanium Tip |
|||
0-120-0018 | Biologics | 25 mm | EUR 100 |
Description: use with corresponding Tapped Tips and Tapped Extender Tips |
Titanium Cup Tip, 250 ml |
|||
0-120-0019 | Biologics | 250 ml | EUR 1377 |
Description: includes Interface Washers |
Microtube Tray, 8 Position (for 250 ml Cup Tip) |
|||
0-120-0021 | Biologics | each | EUR 113 |
Description: includes Interface Washers |
Continuous Flow Chamber |
|||
0-120-0026 | Biologics | each | EUR 774 |
Description: includes Interface Washers |
Interface Washers 1.5” Diameter, 5/Pkg |
|||
0-120-003 | Biologics | 1.5'' Diameter | EUR 31 |
13 mm Diameter Solid Titanium Extender Tip |
|||
0-120-0032 | Biologics | 13 mm | EUR 301 |
13 mm Diameter Tapped Titanium Extender Tip |
|||
0-120-0033 | Biologics | 13 mm | EUR 362 |
19 mm Diameter Solid Titanium Extender Tip |
|||
0-120-0034 | Biologics | 19 mm | EUR 315 |
19 mm Diameter Tapped Titanium Extender Tip |
|||
0-120-0035 | Biologics | 19 mm | EUR 375 |
25 mm Diameter Solid Titanium Extender Tip |
|||
0-120-0036 | Biologics | 25 mm | EUR 328 |
25 mm Diameter Tapped Titanium Extender Tip |
|||
0-120-0037 | Biologics | 25 mm | EUR 389 |
KoldPod, 1.5ml Micro Tube |
|||
0-120-0038 | Biologics | 1.5 ml | EUR 152 |
Description: Thermo conductive tube pods |
KoldPod, 15ml Conical Tube |
|||
0-120-0039 | Biologics | 15 ml | EUR 275 |
Description: Thermo conductive tube pods |
KoldPod, 50ml Conical Tube |
|||
0-120-0040 | Biologics | 50 ml | EUR 290 |
Description: Thermo conductive tube pods |
Model 150 V/T Ultrasonic Homogenizer |
|||
0-121-0002 | Biologics | 210-240V/50-60Hz | EUR 2920 |
Description: Delivers up to 150 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample processing processing. |
Model 300 V/T Ultrasonic Homogenizer |
|||
0-122-0002 | Biologics | 210-240V/50-60Hz | EUR 3520 |
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample. |
SONABOZ Sound Abating Chamber |
|||
0-125-0001 | Biologics | each | EUR 1020 |
Description: Reduces cavitational sound emitted during processing. |
Model 3000 Ultrasonic Homogenizer |
|||
0-127-0002 | Biologics | 210-240V/50-60Hz | EUR 4120 |
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip and includes an intergrated Sound Abating Chmaber to reduce cavitational sound emitted during processing. The Timer and Duty Cycle function increase preciosion in sample. |
Model 3000MP Ultrasonic Homogenizer |
|||
0-128-0002 | Biologics | 210-240V/50-60Hz | EUR 4720 |
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip with preciosion control from a microprocessor and a graphical user interface displayed on a large (145 mm) LCD display. The integrated Sound Abating Chamber reduces cavitational sound emitted during processing. |
OMNICON® Zone Reader, 210-240V/50-60Hz |
|||
0-131-0002 | Biologics | 210-240V/50-60Hz | EUR 35200 |
Description: Designed to Perform multi-plate Assays on round 90/100mm Petri Dishes. The integrated LED illumination system provides transmitted light for brightfield and darkfield illumination of transparent media. |
OMNI-Noculator Peni Cylinder Filler, 210-240V/50-60Hz |
|||
0-134-0002 | Biologics | 210-240V/50-60Hz | EUR 32200 |
Description: A robotic liquid handling system designed to dispense Peni Cylinders and fill Peni Cylinders with the corresponding antibiotic liquid sample. |
Peni Cylinder Dispenser with Manual Hopper |
|||
0-144-0002 | Biologics | each | EUR 5406 |
Description: Dispenser can be configured to dispense 4 or 6 Peni Cylinders onto a petri dish. |
Peni Cylinder Dispenser with Motorized Hopper, 100-240V/50-60Hz |
|||
0-144-0003 | Biologics | 100-240V/50-60Hz | EUR 6254 |
Description: The motorized hopper can be configured to dispense 4 or 6 Peni Cylinders onto a petri Dispenser can be disassembled for disinfection. |
Stainless Steel Peni Cylinder with Flat Face |
|||
0-144-0005 | Biologics | 6mm I.D. x 8mm O.D. x 10mm Long | EUR 399 |
Description: sold in packages of 100 pieces |
Stainless Steel Peni Cylinder with Chamfered Face |
|||
0-144-0006 | Biologics | 6mm I.D. x 8mm O.D. x 10mm Long | EUR 412 |
Description: sold in packages of 100 pieces |
Custom development of ELISAs for other species or antibody isotypes not listed in the catalog. Custom testing of samples for IgG/IgM/IgA or total (IgG+IgM+IgA) |
|||
000-CUS | Alpha Diagnostics | Custom | EUR 602 |
Alpha-Bungarotoxin, CF®405S, 500 ug |
|||
00002 | Biotium | 1UG | EUR 527 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-bungarotoxin, CF405s |
|||
00002 | Cusabio | 500uG | EUR 594 |
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-Bungarotoxin, CF®405S, 500 ug |
|||
00002-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®405S 100ug |
|||
00002-100ug | Biotium | 100uG | EUR 132 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®680R, 500 ug |
|||
9-00003 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®680R, 500 ug |
|||
00003-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®680R 100ug |
|||
9-00003 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®640R, 500 ug |
|||
9-00004 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®640R, 500 ug |
|||
00004-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®640R 100ug |
|||
9-00004 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®488A, 500 ug |
|||
9-00005 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®488A, 500 ug |
|||
00005-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin CF®488A 100ug |
|||
9-00005 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®568, 500 ug |
|||
9-00006 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®568, 500 ug |
|||
00006-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®568 100ug |
|||
9-00006 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®594, 500 ug |
|||
9-00007 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®594, 500 ug |
|||
00007-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin CF®594 100ug |
|||
9-00007 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®633, 500 ug |
|||
9-00009 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®633, 500 ug |
|||
00009-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®633 100ug |
|||
9-00009 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
SARS-CoV-2 Indicator Cell Line for RNA Replication - GFP Reporter only |
|||
0001-PP-001 | IBT Bioservices | 1 cell line (can order x amount) | EUR 12000 |
Description: SARS-CoV-2 GFP reporter cell line using HEK293T (ACE2/TMPRSS2) cells |
Alpha-Bungarotoxin, 1 mg |
|||
00010-1 | Biotium | 1MG | EUR 193 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, 1 mg |
|||
00010-1-1 | Biotium | EA | EUR 193 |
Fluorescein-Alpha-Bungarotoxin, 500 ug |
|||
00011 | Biotium | 500uG | EUR 376 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Fluorescein-Alpha-Bungarotoxin, 500 ug |
|||
00011-1 | Biotium | EA | EUR 376 |
Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug |
|||
00012 | Biotium | 500uG | EUR 394 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug |
|||
00012-1 | Biotium | EA | EUR 394 |
Fluorescein-alpha-bungarotoxin, 10x50ug |
|||
00013 | Biotium | 10ST | EUR 436 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Fluorescein-alpha-bungarotoxin, 10x50ug |
|||
00013-1 | Biotium | EA | EUR 436 |
Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug |
|||
00014 | Biotium | 10ST | EUR 494 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug |
|||
00014-1 | Biotium | EA | EUR 494 |
Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug |
|||
00015 | Biotium | 500uG | EUR 494 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug |
|||
00015-1 | Biotium | EA | EUR 494 |
Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug |
|||
00016 | Biotium | 10ST | EUR 560 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug |
|||
00016-1 | Biotium | EA | EUR 560 |
Biotin-XX-A-Bungarotoxin, 500 ug |
|||
00017 | Biotium | 500uG | EUR 455 |
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Biotin-XX-A-Bungarotoxin, 500 ug |
|||
00017-1 | Biotium | EA | EUR 455 |
Alpha-Bungarotoxin, CF®555, 500 ug |
|||
9-00018 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®555, 500 ug |
|||
00018-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®555 100ug |
|||
9-00018 | Biotium |
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Acrylamide, Chemzymes Ultra Pure® |
|||
00019-100 | Polysciences Europe GmbH | 100g | EUR 101.52 |
Description: 79-06-1 |
Acrylamide, Chemzymes Ultra Pure® |
|||
00019-500 | Polysciences Europe GmbH | 500g | EUR 270 |
Description: 79-06-1 |
Biotin-cAMP, 1 mg |
|||
00020 | Biotium | 1MG | EUR 298 |
Description: N/A |
Biotin-cAMP, 1 mg |
|||
00020-1 | Biotium | 20ST | EUR 298 |
Description: N/A |
Biotin-cAMP, 50 ug |
|||
00020-1-1 | Biotium | EA | EUR 414 |
Biotin-cGMP, 1 mg |
|||
00021 | Biotium | 1MG | EUR 331 |
Description: N/A |
Biotin-cGMP, 1 mg |
|||
00021-1 | Biotium | 20ST | EUR 331 |
Description: N/A |
Biotin-cGMP, 20x50 ug |
|||
00021-1-1 | Biotium | EA | EUR 447 |
Cyanine 644-cAMP, 1 mg |
|||
00022 | Biotium | 1MG | EUR 496 |
Description: N/A |
Cyanine 644-cAMP, 1 mg |
|||
00022-1 | Biotium | 20ST | EUR 496 |
Description: N/A |
Cyanine 644-cAMP, 20x50 ug |
|||
00022-1-1 | Biotium | EA | EUR 647 |
Fluorescein Methotrexate, Triammonium Salt, 1 mg |
|||
00023 | Biotium | 1MG | EUR 285 |
Description: N/A |
Fluorescein Methotrexate, Triammonium Salt, 1 mg |
|||
00023-1 | Biotium | EA | EUR 285 |
Staurosporine |
|||
00025 | Biotium | 100uG | EUR 100 |
Description: N/A |
Staurosporine |
|||
00025-1 | Biotium | EA | EUR 100 |
quotation: istanbul escort
No Comment